Patent ID: 11896614
Assignee: NOVARTIS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 5:
6. The method of claim 1, further comprising acquiring the immune effector cell population from the pediatric subject according to the timing of administration of chemotherapy to the subject in relation to the timing of the immune effector cell acquisition, wherein the chemotherapy or cycle of chemotherapy comprises one or more of an induction, a consolidation, an interim maintenance, a delayed intensification, or a maintenance therapy cycle, and wherein:
(i) the immune effector cell population is acquired from the subject before the subject has undergone a consolidation cycle of chemotherapy or an induction cycle of chemotherapy;
(ii) wherein the immune effector cell population is acquired from the subject before the subject has undergone a consolidation cycle of chemotherapy;
(iii) the subject is classified as having a high-risk or very high-risk cancer and the cells are harvested before the subject has undergone a consolidation cycle;
(iv) the immune effector cell population is acquired from the subject before the subject has undergone a delayed intensification cycle; or
(v) the subject is classified as having a high-risk or very high-risk cancer and the cells are harvested before the subject has undergone a delayed intensification cycle.